Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen's Q1 Revenues Drop 10 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today reported that its first-quarter revenues declined 10 percent year over year.

The Fremont, Calif.-based firm generated total revenues of $351,000 for the three-month period ended March 31, compared to $390,000 for the first quarter of 2010. WaferGen said that its revenues were derived from a combination of one or more of its SmartChip Systems, SmartChip Panels, and/or SmartChip Gene Expression Profiling Services.

The firm's net loss for the quarter was $3.8 million, or $.09 per share, versus a loss of $4.6 million, or $.14 per share, for Q1 2010. For the first quarter of 2011, the company reported an unrealized gain of $491,000 on fair value of warrants, compared to an unrealized loss of $1.9 million for the same quarter in 2010.

WaferGen's R&D expenses increased 40 percent to $2.1 million from $1.5 million, while its SG&A spending jumped 69 percent to $2.2 million from $1.3 million. Its sales and marketing expenses increased primarily due to additional staff and promotional activities following the commercialization of its SmartChip Systems and services.

WaferGen finished the quarter with $3.4 million in cash, cash equivalents, and restricted cash.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.